{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T21:32:20Z","timestamp":1771536740230,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the oncologic outcomes of patients with early-stage endometrioid endometrial cancer (EEC) treated with <jats:italic>in vitro<\/jats:italic> fertilization\/intracytoplasmic sperm injection (IVF\/ICSI) following fertility-sparing treatment (FST).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 62 patients who underwent IVF\/ICSI treatment in a single fertility center between June 2010 and December 2021 after conservative treatment for early-stage EEC were assigned to a recurrence group and a non-recurrence group. Their clinical characteristics and disease outcomes were retrospectively evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 62 women with complete remission (CR) after FST for EEC underwent 103 IVF cycles, resulting in 41 fresh embryo transfers (ETs) and 70 frozen\u2013thawed transfers; 27 (43.55%) achieved clinical pregnancies, and 20 (32.26%) gave birth to a total of 23 live neonates. Additionally, nine patients had live births from natural pregnancies after IVF failure, bringing the cumulative live birth rate to 46.77% (29\/62). After a median follow-up period of 53.88 months (range 20.2\u2013127.5 months), 17 patients (27.42%) experienced recurrence within 2.8 to 57.9 months after the first controlled ovarian stimulation (COS). The probability of relapse at 1, 2, and 3 years after the initiation of COS was 14.52% (9\/62), 21% (13\/62), and 25.81% (16\/62), respectively. Factors such as the time to CR, the time to IVF, the frequency of COS, maintenance treatment before IVF, and histology type were not found to significantly affect recurrence (<jats:italic>p<\/jats:italic> = 0.079, 0.182, 0.093, 0.267, and 0.41, respectively). Live births (hazard ratio (HR): 0.28, 95% CI: 0.082\u20130.962, <jats:italic>p<\/jats:italic> = 0.043) and the protocol of letrozole plus gonadotropin-releasing hormone (GnRH) antagonist\/agonist used during IVF (HR: 0.1, 95% CI: 0.011\u20130.882, <jats:italic>p<\/jats:italic> = 0.038) were identified as independent favorable factors for recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Live birth was associated with decreased recurrence of EEC. Reducing estrogen levels during COS may serve to mitigate the risk of endometrial cancer recurrence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1224622","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:35:49Z","timestamp":1700753749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Analysis of risk factors for recurrence in infertile endometrial cancer patients after in vitro fertilization treatment"],"prefix":"10.3389","volume":"14","author":[{"given":"Hongyi","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caihong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.08.011","article-title":"Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis","volume":"207","author":"Gallos","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.rbmo.2021.06.007","article-title":"IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management","volume":"43","author":"Vaugon","year":"2021","journal-title":"Reprod BioMed Online"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-022-02475-3","article-title":"Analysis of IVF\/ICSI outcomes in infertile women with early-stage endometrial cancer and atypical endometrial hyperplasia after conservative treatment","volume":"39","author":"Guo","year":"2022","journal-title":"J Assist Reprod Genet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.892995","article-title":"Analysis of factors associated with recurrence of early-stage endometrial carcinoma and atypical endometrial hyperplasia in infertile women after in vitro fertilization treatment","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a136312","article-title":"Embryo score to predict implantation after in-vitro fertilization: based on 957 single embryo transfers","volume":"10","author":"Giorgetti","year":"1995","journal-title":"Hum Reprod"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(00)00518-5","article-title":"Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer","volume":"73","author":"Gardner","year":"2000","journal-title":"Fertil Steril"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10815-014-0297-x","article-title":"The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer","volume":"31","author":"Fujimoto","year":"2014","journal-title":"J Assist Reprod Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/ijgc-2018-000036","article-title":"Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer","volume":"29","author":"Chae","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dex368","article-title":"Aromatase inhibitor use during ovarian stimulation suppresses growth of uterine endometrial cancer in xenograft mouse model","volume":"33","author":"Kawahara","year":"2018","journal-title":"Hum Reprod"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0962","article-title":"Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy","volume":"91","author":"Oktay","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"CD008528","DOI":"10.1002\/14651858.CD008528.pub3","article-title":"Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation","volume":"11","author":"Kamath","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05237-2","article-title":"Outcomes of in vitro fertilization cycles following fertility-sparing treatment in stage IA endometrial cancer","volume":"300","author":"Kim","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e38","article-title":"Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology","volume":"34","author":"Ushijima","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4070368","DOI":"10.1155\/2022\/4070368","article-title":"Fertility-sparing approach in patients with endometrioid endometrial cancer grade 2 stage IA (FIGO): A qualitative systematic review","volume":"2022","author":"Giampaolino","year":"2022","journal-title":"BioMed Res Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e21","article-title":"Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility","volume":"29","author":"Yamagami","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001570","article-title":"Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer","volume":"30","author":"He","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11071058","article-title":"Sparing is caring: hormonal retreatment in women with recurrent endometrial cancer after fertility preservation management-A single centre retrospective study","volume":"11","author":"Pino","year":"2023","journal-title":"Healthcare (Basel)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1224622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:35:52Z","timestamp":1700753752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1224622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":17,"alternative-id":["10.3389\/fendo.2023.1224622"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1224622","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"article-number":"1224622"}}